Semaglutide vs tirzepatide
Semaglutide and tirzepatide are the two dominant GLP-1-based medications for weight loss and type 2 diabetes, but they work through different mechanisms. Semaglutide is a pure GLP-1 receptor agonist. Tirzepatide is a dual GLP-1/GIP receptor agonist — it activates two incretin pathways instead of one. The clinical trial data shows tirzepatide producing slightly greater weight loss, while semaglutide has a longer track record and more real-world safety data. Here's a direct comparison across every dimension that matters.
Mechanism: GLP-1 vs GLP-1/GIP dual agonist
The fundamental difference between semaglutide and tirzepatide is the number of incretin receptors each drug activates. Semaglutide targets only the GLP-1 receptor, which drives appetite suppression, delayed gastric emptying, and glucose-dependent insulin release. Tirzepatide targets both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor.
GIP is the other major incretin hormone. In healthy individuals, GIP accounts for roughly 60% of the total incretin effect after a meal — it stimulates insulin release and, at the hypothalamic level, appears to have additional effects on appetite and fat metabolism that complement GLP-1's actions. By activating both pathways simultaneously, tirzepatide produces a broader metabolic effect. Whether this dual mechanism is the primary driver of tirzepatide's slightly greater weight loss, or whether the difference is partly a function of dosing and trial design, is still being studied.
Semaglutide vs tirzepatide for weight loss
The weight loss comparison between semaglutide and tirzepatide draws primarily from two trial programs: the STEP trials for semaglutide and the SURMOUNT trials for tirzepatide. Both enrolled adults with obesity and measured weight loss over similar timeframes.
| Metric | Semaglutide 2.4 mg (STEP 1) | Tirzepatide 15 mg (SURMOUNT-1) |
|---|---|---|
| Average weight loss | 14.9% | 22.5% |
| Patients losing ≥20% | 32% | 57% |
| Patients losing ≥5% | 86% | 96% |
| Trial duration | 68 weeks | 72 weeks |
| Participants | 1,961 | 2,539 |
| Population | BMI ≥30 (or ≥27 + comorbidity), no T2D | BMI ≥30 (or ≥27 + comorbidity), no T2D |
Tirzepatide at its highest dose (15 mg) produced roughly 7.5 percentage points more weight loss than semaglutide 2.4 mg. This is a clinically meaningful difference — for a 220-pound person, it represents approximately 16 additional pounds of weight loss. However, the comparison has important caveats. The trials were not head-to-head (they used different placebo groups and slightly different enrollment criteria). Tirzepatide's 15 mg dose may not be directly comparable to semaglutide's 2.4 mg dose in terms of relative potency. And individual variation in both trials was wide — the distributions overlapped significantly, meaning many patients on semaglutide outperformed many patients on tirzepatide.
A direct head-to-head trial (SURPASS-2) compared tirzepatide against semaglutide 1.0 mg — the diabetes dose, not the weight loss dose — and found tirzepatide superior. However, no published trial has compared tirzepatide 15 mg against semaglutide 2.4 mg directly. Until that data exists, the cross-trial comparison above is the best available evidence.
Semaglutide vs tirzepatide for type 2 diabetes
For type 2 diabetes, both semaglutide and tirzepatide produce substantial A1C reductions. In the SURPASS-2 trial — the only direct head-to-head — tirzepatide (at all three doses: 5, 10, and 15 mg) produced greater A1C reductions than semaglutide 1.0 mg. The tirzepatide 15 mg group achieved an average A1C reduction of 2.30% compared to 1.86% for semaglutide 1.0 mg, and a higher proportion of tirzepatide patients reached A1C below 7.0% (92% vs 81%).
That said, both medications are highly effective for diabetes management. The practical difference between a 1.86% and a 2.30% A1C reduction, while statistically significant, may be clinically marginal for many patients — both bring the average patient from poorly controlled to well-controlled diabetes. The choice between the two for diabetes management often depends more on cost, insurance coverage, side effect tolerance, and availability than on the modest efficacy difference.
Semaglutide vs tirzepatide side effects
The side effect profiles of semaglutide and tirzepatide are similar, which is expected given that both activate the GLP-1 receptor (tirzepatide additionally activates GIP). Gastrointestinal side effects dominate both drugs.
| Side effect | Semaglutide 2.4 mg (STEP 1) | Tirzepatide 15 mg (SURMOUNT-1) |
|---|---|---|
| Nausea | 44% | 31% |
| Diarrhea | 32% | 23% |
| Vomiting | 25% | 13% |
| Constipation | 24% | 11% |
| Discontinuation (GI) | 4–7% | 4–6% |
At first glance, tirzepatide appears to have a milder GI side effect profile — lower rates of nausea, diarrhea, vomiting, and constipation. However, this comparison is complicated by differences in trial design, titration speed, and patient populations. The discontinuation rates due to GI side effects are similar for both drugs (4–7% range), which suggests that the real-world tolerability may be more comparable than the raw incidence rates imply. For detailed semaglutide side effect management, see the semaglutide side effects page.
Semaglutide vs tirzepatide cost
Cost is often the deciding factor between semaglutide and tirzepatide in practice. Both branded medications are expensive at list price — semaglutide costs approximately $900–$1,350 per month and tirzepatide costs approximately $1,000–$1,200 per month. Insurance coverage varies significantly by plan and indication; some plans cover one but not the other.
Compounded semaglutide is widely available from compounding pharmacies at lower cost ($150–$500/month), which gives semaglutide a significant access advantage for patients paying out of pocket. Compounded tirzepatide has had a more complicated regulatory path — the FDA's removal of tirzepatide from the shortage list in 2024 restricted compounding pharmacy access more quickly than for semaglutide. For detailed pricing, see the semaglutide cost page.
Which is better: semaglutide or tirzepatide?
Neither semaglutide nor tirzepatide is categorically "better" — the right choice depends on the patient's primary goal, insurance coverage, cost tolerance, and side effect profile. Tirzepatide appears to produce modestly greater weight loss at the highest dose, which may matter for patients seeking maximum weight reduction. Semaglutide has a longer real-world track record (approved since 2017 vs 2022 for tirzepatide), more published safety data, a proven cardiovascular benefit (SUSTAIN-6), an oral formulation option, and broader compounded availability.
For patients with type 2 diabetes and cardiovascular risk, semaglutide has the stronger evidence base for cardiovascular outcomes. For patients whose primary concern is maximizing weight loss and who have insurance coverage for tirzepatide, the SURMOUNT data favors tirzepatide. For patients paying out of pocket who need an affordable option, compounded semaglutide is currently more accessible and less expensive than compounded tirzepatide.
Can you switch from semaglutide to tirzepatide?
Yes, switching is possible and is done in clinical practice. Most prescribers start tirzepatide at the lowest dose (2.5 mg) regardless of the patient's prior semaglutide dose, then titrate up following the standard tirzepatide schedule. GI side effects during the switch tend to be milder than a first-time start, since the patient's GI system is already adapted to GLP-1 receptor activation.
Is tirzepatide more effective than semaglutide?
At the highest approved doses, tirzepatide produces slightly greater average weight loss (22.5% vs 14.9%) and slightly greater A1C reduction (2.30% vs 1.86%) compared to semaglutide. However, these comparisons are mostly cross-trial rather than head-to-head, individual responses vary widely, and both medications are highly effective. The clinical difference may not be meaningful for all patients.
Does tirzepatide have fewer side effects than semaglutide?
The raw incidence rates in clinical trials suggest tirzepatide may cause somewhat less nausea and vomiting than semaglutide. However, discontinuation rates due to side effects are similar for both drugs, and cross-trial comparisons of side effect rates are inherently imprecise. The real-world tolerability appears comparable.